Clinical Trial Update: GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update reports on a Phase 1 study of GC012F Injection for refractory generalized myasthenia gravis, with the study currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• GC012F Injection

Snippet

Sponsor: Daishi Tian | Conditions: Generalized Myasthenia Gravis (gMG) | EARLY_Phase 1 | Status: RECRUITING